Kwang Dong Pharmaceutical challenges to the obesity treatment market with the best selling drug ‘Contrave’
Kwang Dong Pharmaceutical(President Sung-won Choi) will enter the obesity treatment market.
Kwang Dong Pharmaceutical announced on the 10th that it has established the domestic contract to exclusively sell the obesity treatment new drug, Contrave, with an U.S. biopharmaceutical company, Orexigen...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
